

23<sup>rd</sup> January, 2024

<p><b>To,</b> <b>Department of Corporate Services</b> <b>BSE Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p><b>Ref.: Scrip Code No. : 540701 (Equity)</b> <b>: 974556 (Debt)</b></p>	<p><b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p><b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b></p>
--	--

**SUB.: DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS, 2015: COMPANY’S BAVLA SITE RECEIVED GMP COMPLIANCE INSPECTION RESULT FROM JAPANESE PMDA**

Dear Sir,

With reference to the captioned subject, pl. note that on 9<sup>th</sup> August, 2023 Company has intimated to the Stock Exchanges that the Company’s Bavla site was successfully inspected by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) during 31<sup>st</sup> July, 2023 to 3<sup>rd</sup> August, 2023 and the final report is awaited.

Now, we are pleased to share that today we have received an intimation regarding our Bavla site has been declared GMP Compliant by the PMDA.

Kindly take this on your record.

Thanking You,

Yours faithfully,  
**For, Dishman Carbogen Amcis Limited**

**Shrima Dave**  
**Company Secretary**